en · de · es
epitalon-notes.peptides1126.com › Info › Analytical Characterization And Stability — Hands-On Walkthrough

Analytical Characterization And Stability — Hands-On Walkthrough

By Editorial Desk · published 2025-10-06 · last reviewed 2025-11-01 · Info

Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Characterization and Stability

Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.

Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.

Epitalon Background And Identification

The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.

Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.

Epitalon at a glance

PropertyValueNotes
Analytical methodReversed-phase HPLCPurity determination, typically 214 nm
Mass confirmationESI or MALDI mass spectrometryCompared with mass near 390 Da
Common synonymsEpitalon, epithalon, AEDGNaming differs between suppliers
Storage temperature−20 °C or lowerLyophilised powder, kept desiccated
Solution stabilityLimited in neutral aqueous bufferAspartimide and hydrolysis pathways

Laboratory Handling Storage and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.

Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.

Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.

Related pages on this site

Identity and Research Background

Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Analytical Methods and Storage

Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.

Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.

Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.

Peptide Identity and Laboratory Handling

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.

Reference notes

Abatacept, sold under the brand name Orencia, is a medication used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. It is a modified antibody. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. In order for a T cell to be activated and produce an immune response, an antigen-presenting cell must present two signals to the T cell. One of those signals is the major histocompatibility complex (MHC), combined with the antigen, and the other signal is the CD80 or CD86 molecule (also known as B7-1 and B7-2). Abatacept binds to the CD80 and CD86 molecule, and prevents the second signal. Without the second signal, the T cell can't be activated. Abatacept was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy. Abatacept received approval from the FDA in 2005.

Finding the structure of proteins is an important application of bioinformatics. The Critical Assessment of Protein Structure Prediction (CASP) is an open competition where worldwide research groups submit protein models for evaluating unknown protein models.

Quicksand is a shear thinning non-Newtonian colloid that gains viscosity at rest. Quicksand's non-Newtonian properties can be observed when it experiences a slight shock (for example, when someone walks on it or agitates it with a stick), shifting between its gel and sol phase and seemingly liquefying, causing objects on the surface of the quicksand to sink.

The yolk sac (2) surrounding the yolk (3) contains protein and fat rich nutrients that are absorbed by the embryo via vessels (4) that allow the embryo to grow and metabolize. The air space (7) provides the embryo with oxygen while it is hatching. This ensures that the embryo will not suffocate while it is hatching. There are no larval stages of development. Viviparity and ovoviviparity have evolved in squamates and many extinct clades of reptiles. Among squamates, many species, including all boas and most vipers, use this mode of reproduction. The degree of viviparity varies; some species simply retain the eggs until just before hatching, others provide maternal nourishment to supplement the yolk, and yet others lack any yolk and provide all nutrients via a structure similar to the mammalian placenta. The earliest documented case of viviparity in reptiles is the Early Permian mesosaurs, although some individuals or taxa in that clade may also have been oviparous because a putative isolated egg has also been found. Several groups of Mesozoic marine reptiles also exhibited viviparity, such as mosasaurs, ichthyosaurs, and Sauropterygia, a group that includes pachypleurosaurs and Plesiosauria. Asexual reproduction has been identified in squamates in six families of lizards and one snake. In some species of squamates, a population of females is able to produce a unisexual diploid clone of the mother.

This would prevent its commercial development and obligate the owner to maintain it properly. OHS objected. The Ontario Conservation Review Board heard arguments for and against designation in September 2007 and recommended designation of the entire property in October. The Town officially passed the designation by-law on November 12, 2007. Banting's artwork has gained attention in the art community; A painting of his called "St. Tîte des Cap" sold for Can$30,000 including buyer's premium at a Canadian art auction in Toronto.

Sources: en.wikipedia.org

Notes from published material

== Case studies: environmental impact on hemocyanin levels == A 2003 study of the effect of culture conditions of blood metabolites and hemocyanin of the white shrimp Litopenaeus vannamei found that the levels of hemocyanin, oxyhemocyanin in particular, are affected by the diet. The study compared oxyhemocyanin levels in the blood of white shrimp housed in an indoor pond with a commercial diet with that of white shrimp housed in an outdoor pond with a more readily available protein source (natural live food) as well. Oxyhemocyanin and blood glucose levels were higher in shrimp housed in outdoor ponds. It was also found that blood metabolite levels tended to be lower in low activity level species, such as crabs, lobsters, and the indoor shrimp when compared to the outdoor shrimp. This correlation is possibly indicative of the morphological and physiological evolution of crustaceans. The levels of these blood proteins and metabolites appear to be dependent on energetic demands and availability of those energy sources.

=== Chadder's infringement lawsuit (2007) === In June 2007, the company filed a lawsuit against an American Fork, Utah, restaurant named Chadder's for trademark infringement, claiming that the "look and feel" of the restaurant too closely resembled that of In-N-Out, and that the restaurant violated trademarked menu items, such as "Animal Style", "Protein Style", and the "Double-Double". The company learned about this from Utah customers contacting the customer service department asking if In-N-Out opened a location in Utah under a different name or if they had any affiliation with the restaurant in any way. Several customers stated they ordered trademarked items such as Animal and Protein styles. Utah District Court Judge Ted Stewart issued a temporary restraining order against the look-alike. Chadder's opened another location near the Salt Lake City area and one in Provo. In 2009, In-N-Out opened a restaurant in American Fork less than a mile from the Chadder's restaurant. Per their website, Chadder's started selling a "Stubby Double" instead of "Double Double". The Chadder's restaurants in Utah have gone out of business since In-N-Out restaurants have opened in Utah.

Australian work relationships begin with a contract, and carry basic rights for fair pay and conditions. Most rights are for "employees" (not the self-employed) who are defined by the reality of systematic unequal bargaining power compared to employers, usually organised in a corporate form. By law, rights are more important than contract terms that employers impose. A contract is a deal entered into by consent, and common law and statute set default rights, such as enough hours, a safe system of work, and sometimes good faith. Further, under the Fair Work Act 2009, the Fair Work Commission sets a national minimum wage, a system of minimum pay scales in modern awards, and oversees collective bargaining between unions and employers. The National Employment Standards also set a floor of rights for a standard maximum 38 hour week, at least 28 to 37 days of annual leave and public holidays, and long service leave. Modern awards set by the Fair Work Commission, for 150 workplace sectors in 2024, must contain terms on working time, consultation before changes, disputes, and flexibility, and usually contain further rights such as higher overtime pay, rest breaks, more holidays, and superannuation to ensure people a decent retirement income. There are also rights to paid parental leave, at a minimum of 20 weeks shared between parents, and the FWC has a duty to end the gender pay gap, given the prior failure to equalise and lengthen parental leave in awards and collective agreements.

Catulle Mendès adapted Medea into his play Medée in 1898, in three acts and in verse. Alfons Mucha drew a poster for a performance of this play starring Sarah Bernhardt. Jean Anouilh adapted the Medea story in his French drama Médée in 1946. Robinson Jeffers adapted Medea into a hit Broadway play in 1947, in a famous production starring Judith Anderson, the first of three actresses to win a Tony Award for the role. It was directed by John Gielgud, who co-starred as Jason. Medea opened on Broadway at the National Theatre on 20 October 1947, transferred to the Royale Theatre on 15 December, and closed on 15 May 1948, after 214 performances. At the 2nd Tony Awards on 28 March 1948, Judith Anderson shared (with Katharine Cornell and Jessica Tandy) the Award for Best Actress in a Play. Another staging, produced and directed by Guthrie McClintic at the City Center, premiered on 2 May 1949, and closed, after 16 performances, on 21 May. A staging in 1982, at the Cort Theatre, brought a Tony win for Zoe Caldwell, who played Medea, and a Best Featured Actress in a Play nomination for Judith Anderson as Nurse. With a subsequent Tony win for Diana Rigg in 1994, the play holds the American Theatre Wing's Tony Award record for most wins for the same female lead character in a play. Ben Bagley's Shoestring Revue performed a musical parody off-Broadway in the 1950s which was later issued on an LP and a CD, and was revived in 1995. The same plot points take place, but Medea in Disneyland is a parody, in that it takes place in a Walt Disney animated cartoon.

On 9 January 2024, the Kata'ib Hezbollah spokesperson Jafar al-Husseini warned that the Islamic Resistance in Iraq would help Hezbollah fight Israel if war erupted between the two sides. This statement was a few weeks after the Islamic Resistance in Iraq claimed responsibility for a drone attack on a Karish rig which Lebanon claims to hold sovereignty to. On 23 June 2024, the spokesperson to Kata'ib Sayyid al-Shuhada Kadhem al-Fartousi said the brigade will join Hezbollah's side if Israel decides to launch a full-blown war in Lebanon. On 24 June 2024, Qais al-Khazali, the leader of Asa'ib Ahl al-Haq, stated in a televised speech that if the U.S. continued to support Israel in expanding the war to Lebanon and Hezbollah, the group would begin to attack US interests in Iraq and the Middle East.

Sources: en.wikipedia.org

Background from the literature

Additionally, a new research program called ACTINET has been started in the EU to make transmutation possible on an industrial scale. According to U. S. President Bush's Global Nuclear Energy Partnership (GNEP) of 2007, the United States is actively promoting research on transmutation technologies needed to markedly reduce the problem of nuclear waste treatment. There have also been theoretical studies involving the use of fusion reactors as so-called "actinide burners" where a fusion reactor plasma such as in a tokamak, could be "doped" with a small amount of the "minor" transuranic atoms which would be transmuted (meaning fissioned in the actinide case) to lighter elements upon their successive bombardment by the very high energy neutrons produced by the fusion of deuterium and tritium in the reactor. A study at MIT found that only two or three fusion reactors with parameters similar to that of the International Thermonuclear Experimental Reactor (ITER) could transmute the entire annual minor actinide production from all of the light-water reactors presently operating in the United States fleet while simultaneously generating approximately one gigawatt of power from each reactor. Opportunities for managing nuclear waste by transmutation are also being explored in linear particle accelerators.

Insulin degludec/liraglutide is a fixed-dose combination medication used to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise. It consists of insulin degludec and liraglutide and is administered through subcutaneous injection. Gastrointestinal side effects include nausea, diarrhea, vomiting, constipation, dyspepsia (indigestion), gastritis (stomach inflammation), abdominal pain, flatulence, gastroesophageal reflux disease (acid reflux), and abdominal distension. Severe symptomatic hypoglycemia was reported in a small number of patients during clinical trials. Insulin degludec functions as a replacement insulin, facilitating glucose uptake into cells and thereby reducing the symptoms and complications of diabetes. It differs slightly from human insulin, as it is absorbed more gradually and consistently, allowing for prolonged action. Liraglutide, a GLP-1 receptor agonist, mimics the effects of incretin hormones by enhancing insulin secretion from the pancreas in response to food intake, thereby aiding blood glucose regulation. Insulin degludec/liraglutide is sold by Novo Nordisk under the name Xultophy.

Substrate-level phosphorylation: 2 ATP from glycolysis + 2 ATP (directly GTP) from Krebs cycle Oxidative phosphorylation 2 NADH+H+ from glycolysis: 2 × 1.5 ATP (if glycerol phosphate shuttle transfers hydrogen atoms) or 2 × 2.5 ATP (malate-aspartate shuttle) 2 NADH+H+ from the oxidative decarboxylation of pyruvate and 6 from Krebs cycle: 8 × 2.5 ATP 2 FADH2 from the Krebs cycle: 2 × 1.5 ATP Altogether this gives 4 + 3 (or 5) + 20 + 3 = 30 (or 32) ATP per molecule of glucose These figures may still require further tweaking as new structural details become available. The above value of 3 H+ / ATP for the synthase assumes that the synthase translocates 9 protons, and produces 3 ATP, per rotation. The number of protons depends on the number of c subunits in the Fo c-ring, and it is now known that this is 10 in yeast Fo and 8 for vertebrates. Including one H+ for the transport reactions, this means that synthesis of one ATP requires 1 + 10/3 = 4.33 protons in yeast and 1 + 8/3 = 3.67 in vertebrates. This would imply that in human mitochondria the 10 protons from oxidizing NADH would produce 2.72 ATP (instead of 2.5) and the 6 protons from oxidizing succinate or ubiquinol would produce 1.64 ATP (instead of 1.5). This is consistent with experimental results within the margin of error described in a recent review. The total ATP yield in ethanol or lactic acid fermentation is only 2 molecules coming from glycolysis, because pyruvate is not transferred to the mitochondrion and finally oxidized to the carbon dioxide (CO2), but reduced to ethanol or lactic acid in the cytoplasm.

=== June === On June 1, Davido and Organized Noize were inducted into the Black Music & Entertainment Walk of Fame. On June 2, Peabo Bryson died at the age of 75. On June 3, James Blood Ulmer died at the age of 86. On June 5, Talay Riley was killed at the age of 35. On June 13, the intersection of Grumman Avenue and Elizabeth Avenue in Newark, New Jersey was named Faith Evans Way. On June 16, Flo was awarded the ASCAP Vanguard Award. On June 22, Clive Davis died at the age of 94. On June 25, Leon Thomas was awarded the ASCAP Vanguard Award. On June 28, the BET Awards 2026 were held. Kehlani won Video of the Year for "Folded" and Best Female R&B/Pop Artist. Mariah the Scientist won the Viewer's Choice Award for "Burning Blue". Leon Thomas won Best Male R&B/Pop Artist. Olivia Dean won Best New Artist. Teyana Taylor won Video Director of the Year and received the Icon of the Year Award. Lauryn Hill received the Living Legend Icon Award.

The two substrates of this enzyme are xanthoxin and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are abscisic aldehyde, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is xanthoxin:NAD+ oxidoreductase. Other names in common use include xanthoxin oxidase, and ABA2. This enzyme participates in carotenoid biosynthesis.

Sources: en.wikipedia.org

Frequently asked questions

Why is ultraviolet detection at 214 nanometres used?

The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.

What conditions degrade epitalon in solution?

Neutral and slightly basic aqueous conditions promote aspartimide formation at the aspartate-glycine step, often followed by deamidation. Elevated temperature and repeated freeze-thaw cycles accelerate the loss. Acidic solutions and dry lyophilised powder are comparatively stable over short periods.

Is there a pharmacopoeial standard for epitalon?

No monograph exists in the United States Pharmacopeia or the European Pharmacopoeia, and no widely distributed certified reference standard is available. Purity and identity therefore rest on supplier methods that are not harmonised. This absence is the main reason reported purities are difficult to compare between sources.

What is epitalon derived from?

It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.

Network